ReviewAdipocyte2020
RAGE signalling in obesity and diabetes: focus on the adipose tissue macrophage.
Review in Adipocyte, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Exploring the material basis and potential mechanism of spleen-strengthening and damp-resolving prescriptions in the treatment of diabetes mellitus complicated with obesity based on data mining, UPLC-Q-TOF-MS/MS and network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- DAMP signaling networks: from receptors to diverse pathophysiological functions.Journal of advanced research · 2026Review
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Gender differences in adiponectin levels among obese individuals and their association with cardiovascular disease.Frontiers in cell and developmental biology · 2026Review
- Type 2 Diabetes Promotes the Microglial Pyroptosis by Activating NLRP3 Inflammasome to Impede Remyelination After Spinal Cord Injury.Research (Washington, D.C.) · 2026Article
- Microenvironmental determinants of cancer progression during obesity: emerging evidence and novel perspectives.Journal of translational medicine · 2025Review
- Relationship between sRAGE and obesity in individuals with type 1 diabetes during a median follow-up of 6.3 years.Diabetologia · 2025Article
- Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys.International journal of molecular sciences · 2025Review
- Obesity drives depot-specific vascular remodeling in male white adipose tissue.Nature communications · 2025Article
- Targeting RAGE-signaling pathways in the repair of rotator-cuff injury.Molecular and cellular biochemistry · 2025Review
- Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls.Calcified tissue international · 2025Observational
- Review
- The Multifaceted S100B Protein: A Role in Obesity and Diabetes?International journal of molecular sciences · 2024Review
- RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity.Cell reports. Medicine · 2023Article
- 1,3-Butanediol Administration Increases β-Hydroxybutyrate Plasma Levels and Affects Redox Homeostasis, Endoplasmic Reticulum Stress, and Adipokine Production in Rat Gonadal Adipose Tissue.Antioxidants (Basel, Switzerland) · 2023Article
- Implications of receptor for advanced glycation end products for progression from obesity to diabetes and from diabetes to cancer.World journal of diabetes · 2023Review
- The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.Journal of experimental & clinical cancer research : CR · 2023Article
- Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy.Endocrine reviews · 2023Review
- Mechanism of immune attack in the progression of obesity-related type 2 diabetes.World journal of diabetes · 2023Review
- NWorld journal of diabetes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advanced glycosylation end product receptor (RAGE) acts as a recognition receptor and interacts with different types of ligands that form and accumulate in the tissues and circulation, such as diabetes, inflammation, insulin resistance, and obesity. In these environments, RAGE is expressed on the surface of various cells associated with tissue disturbance. This review mainly summarizes the characteristics of RAGE-related signalling, with a particular emphasis on the role of RAGE in the development of obesity. We also briefly describe the phenotypes and characteristics of macrophages and focus on the role of adipose tissue macrophages (ATMs) and the regulatory mechanisms in obesity, diabetes, and other related metabolic diseases. Besides, we will also elaborate on the prospect of new strategies for treating diabetes and obesity-related metabolic diseases by inhibiting RAGE signalling and regulating ATMs recruitment and polarization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.